Tvardi Therapeutics (TVRD)
NASDAQ:TVRD
TVRD Stock Chart & Stats
$3.36
--
Market closed
$3.36
--
Day’s Range― - ―
52-Week Range$3.36 - $43.65
Previous CloseN/A
VolumeN/A
Average Volume (3M)401.55K
Market Cap
$31.52M
Enterprise Value$9.67M
Total Cash (Recent Filing)$36.46M
Total Debt (Recent Filing)$228.00K
Price to Earnings (P/E)―
Beta0.21
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,381,344
10 Day Avg. Volume1,070,842
30 Day Avg. Volume401,545
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.62
Price to Sales (P/S)1.04
P/FCF Ratio-0.12
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue2.40
Enterprise Value/Gross Profit2.46
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$9.00Price Target Upside167.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsPost‑hoc analyses from the Phase 2 REVERT study reported consistent favorable trends across lung imaging, fibrosis biomarkers, and functional measures for TTI‑101 versus placebo, suggesting a potential anti‑fibrotic effect that could attract investor interest if replicated.
Mechanism And Broader Pipeline PotentialBiomarker changes aligning with STAT3 inhibition and unusually strong interim response signals in hepatocellular carcinoma studies provide biological validation that could enhance the program's clinical and commercial outlook.
Next‑generation FormulationA next‑generation prodrug was designed to improve gastrointestinal tolerability and bioavailability, and first‑in‑human data showing rapid conversion to the active compound with comparable exposure would support better clinical positioning.
Bears Say
Research Conflicts Of InterestDisclosure that the covering firm conducts business with companies it covers introduces potential conflicts of interest that may affect perceived objectivity of analyst reports and investor confidence.
Safety And Tolerability ConcernsHigher rates of adverse‑event‑driven treatment discontinuations, particularly in combination treatment arms with gastrointestinal side effects, raise tolerability questions that could complicate development and regulatory paths.
Trial InterpretabilityTopline efficacy was difficult to interpret after many treated patients discontinued and placebo performance exceeded historical expectations, creating uncertainty around the true magnitude of any treatment benefit.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Tvardi Therapeutics lowest stock price was $3.36 and its highest was $43.65 in the past 12 months.
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is $31.52M.
When is Tvardi Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tvardi Therapeutics’s earnings last quarter?
Currently, no data Available
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tvardi Therapeutics have?
Tvardi Therapeutics has 9,381,344 shares outstanding.
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tvardi Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (167.86% Upside)
$9.00 (167.86% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-31.48%
12-Months-Change
Fundamentals
Return on Equity
-135.79%
Trailing 12-Months
Asset Growth
-23.98%
Trailing 12-Months
Company Description
Tvardi Therapeutics
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
TVRD Stock 12 Month Forecast
Average Price Target
$9.00
▲(167.86% Upside)
Technical Analysis
Plus Therapeutics
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―
Ownership Overview
12.88% Insiders
7.86% Mutual Funds
12.51% Other Institutional Investors
60.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---